Menu Search
Equities

Bachem Holding AG

BANB:SWX

Bachem Holding AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CHF)68.70
  • Today's Change-1.10 / -1.58%
  • Shares traded34.51k
  • 1 Year change-2.83%
  • Beta1.1659
Data delayed at least 15 minutes, as of Nov 22 2024 14:27 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CHFIncome statement in CHFView more

Year on year Bachem Holding AG grew revenues 8.57% from 531.74m to 577.32m while net income improved 11.10% from 100.68m to 111.86m.
Gross margin31.04%
Net profit margin19.66%
Operating margin22.40%
Return on assets7.05%
Return on equity8.88%
Return on investment8.10%
More ▼

Cash flow in CHFView more

In 2023, Bachem Holding AG increased its cash reserves by 401.49%, or 126.27m. The company earned 249.86m from its operations for a Cash Flow Margin of 43.28%. In addition the company generated 48.69m cash from financing while 170.81m was spent on investing.
Cash flow per share2.15
Price/Cash flow per share32.48
Book value per share17.42
Tangible book value per share17.23
More ▼

Balance sheet in CHFView more

Bachem Holding AG uses little debt in its capital structure as supported by a debt to capital ratio of 0.02%.
Current ratio3.41
Quick ratio1.57
Total debt/total equity0.0002
Total debt/total capital0.0002
More ▼

Growth rates in CHF

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 6.67% and 9.68%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
Div yield(5 year avg)0.88%
Div growth rate (5 year)7.78%
Payout ratio (TTM)52.83%
EPS growth(5 years)16.88
EPS (TTM) vs
TTM 1 year ago		14.83
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.